You just read:

Frost & Sullivan Publishes Update Coverage Report on DNA Biomedical Solutions Ltd.: Entera's unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

News provided by

Frost & Sullivan

06 Feb, 2018, 09:22 GMT